Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.50 |
| ▸ | NMT1 | P30419 | 4/20 | 0.40 |
| ▸ | PDE5A | O76074 | 11/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706222 | 0.84 | TERT (0.49) | TERTPDE5A | |
| SCHEMBL1705329 | 0.82 | TERT (0.61) | TERTPDE5A | |
| SCHEMBL6284529 | 0.81 | TERT (0.53) | TERT | |
| SCHEMBL4741016 | 0.81 | PDE5A (0.58) | TERTPDE5A | |
| SCHEMBL7006683 | 0.80 | TERT (0.58) | TERTPDE5A | |
| SCHEMBL5739977 | 0.79 | PDE5A (0.34) | PDE5A | |
| SCHEMBL4900976 | 0.79 | TERT (0.50) | TERTPDE5APDE3BPDE3A | |
| SCHEMBL8055436 | 0.79 | PDE5A (0.56) | TERTPDE5A | |
| SCHEMBL4565717 | 0.78 | TERT (0.56) | TERTPDE5APDE3BPDE3A | |
| SCHEMBL8055439 | 0.77 | TERT (0.54) | TERTPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299389-B1 | A PROCESS FOR PREPARING PYRAZOLOPYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF IMPOTENCE | DONG A PHARM CO LTD (KR) | 2006-10-04 | — | — | EP | disclosed |
| EP-1299389-A4 | A PROCESS FOR PREPARING PYRAZOLOPYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF IMPOTENCE | DONG A PHARM CO LTD (KR) | 2005-02-02 | — | — | EP | disclosed |
| US-6844436-B2 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | DONG A. PHARM. CO., LTD. (KR) | 2005-01-18 | — | — | US | disclosed |
| US-20030176696-A1 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | MEZZION PHARMA CO., LTD. (KR) | 2003-09-18 | — | — | US | disclosed |
| EP-1299389-A1 | A PROCESS FOR PREPARING PYRAZOLOPYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF IMPOTENCE | Dong A Pharmaceutical Co. Ltd. (KR) | 2003-04-09 | — | — | EP | disclosed |
| WO-2001098304-A1 | A PROCESS FOR PREPARING PYRAZOLOPYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF IMPOTENCE | DONG A PHARM. CO., LTD. (KR) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176696-A1 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | PDE3B, PDE8B, PDE5A | TERT 4593/4885NMT1 2623/4885PDE5A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.